Healthcare

Medicare at 50 Act

United States · United States Congress · 13 February 2019

Medicare at 50 Act This bill establishes a Medicare buy-in option for certain qualifying individuals and also repeals restrictions relating to prescription drug prices under the Medicare prescription drug benefit. Specifically, the bill allows individuals aged 50 to 64 to enroll in Medicare if such individuals would otherwise qualify for Medicare at the age of 65. The Centers for Medicare & Medicaid Services (CMS) must determine enrollment periods and set premiums for the buy-in option established under the bill, in accordance with specified requirements. The CMS must also award grants to states and nonprofit organizations for outreach and enrollment activities relating to the buy-in option. The bill also repeals provisions that prohibit the CMS from negotiating the prices of prescription drugs or from establishing a formulary under the Medicare prescription drug benefit.

Native American Suicide Prevention Act of 2019

United States · United States Congress · 13 February 2019

Native American Suicide Prevention Act of 2019 This bill requires a state or state-designated entity that receives support from the Substance Abuse and Mental Health Services Administration for development and implementation of a statewide youth suicide early intervention and prevention strategy to agree to collaborate with each of the state's federally recognized Indian tribes, tribal organizations, urban Indian organizations, and Native Hawaiian health care systems regarding the strategy.

Protecting Americans with Pre-existing Conditions Act of 2019

United States · United States Congress · 13 February 2019

Protecting Americans with Pre-existing Conditions Act of 2019 This bill nullifies the Department of the Treasury and the Department of Health and Human Services guidance titled "State Relief and Empowerment Waivers," published on October 24, 2018. The guidance pertains to Section 1332 waivers (also known as State Innovation Waivers or State Relief and Empowerment Waivers), which allow states to forego certain requirements of the Patient Protection and Affordable Care Act in order to implement experimental plans for health care coverage, as long as the resulting coverage meets certain statutory criteria. The guidance, which supersedes earlier guidance from 2015, alters agency interpretation of how states may satisfy the statutory criteria for waiver approval. For example, the guidance (1) redefines acceptable coverage under such waivers to include short-term, limited-duration insurance and association health plans; (2) allows the comprehensiveness and affordability of coverage under such waivers to be assessed based on projected availability, rather than enrollment; and (3) allows the level of coverage to be assessed based on the effects over the entire course of the waiver, rather than per year.

MORE Health Education Act

United States · United States Congress · 12 February 2019

Marketing and Outreach Restoration to Empower Health Education Act of 2019 or the MORE Health Education Act This bill requires the Department of Health and Human Services (HHS) to conduct outreach and educational activities regarding federally-facilitated exchanges (i.e., health insurance exchanges that are established and operated within states by HHS). The activities must inform potential enrollees of the availability of coverage and related financial assistance under the exchanges and must be provided in culturally and linguistically appropriate formats.

Expanding Transparency of Information and Safeguarding Toxics (EtO is Toxic) Act of 2019

United States · United States Congress · 12 February 2019

Expanding Transparency of Information and Safeguarding Toxics (EtO is Toxic) Act of 2019 This bill updates requirements for chemicals that pose an adverse public health risk. Specifically, the bill requires the Environmental Protection Agency (EPA) to publish an updated National Air Toxics Assessment once every two years. The assessment uses emissions data to estimate health risks from toxic air pollutants. The bill also requires the EPA to use data from its Integrated Risk Information System when conducting rulemaking with respect to chemicals that have been assessed in the system. For chemicals that are found to pose an adverse health risk, the EPA shall identify and do additional review on facilities that are significant sources of the chemical to determine whether the facility poses an adverse public health risk. Under the bill, chemicals identified as carcinogenic in the system must have a toxic chemical release form completed by the owner or operator of a facility. The bill requires the Department of Health and Human Services (HHS) to consult with appropriate EPA offices regarding the future schedule of assessments of chemicals to be conducted under the system, the results or existing assessments, and concerns that may merit additional review. HHS must also administer personal exposure tests for chemicals that pose a new adverse public health risk to vulnerable populations, such as children. HHS must establish a Community Outreach Division to communicate risk assessments to affected communities.

Expressing the sense of Congress regarding the provision of a basic standard of humanitarian care to all individuals in U.S. Customs and Border Protection custody.

United States · United States Congress · 11 February 2019

This concurrent resolution expresses the sense of Congress that the United States must provide a basic standard of humanitarian care to all individuals in its custody. In particular, the resolution urges U.S. Customs and Border Protection to provide adequate care, including health care, living accommodations, and sanitation to those in its custody.

Educating Consumers on the Risks of Short-Term Plans Act of 2019

United States · United States Congress · 11 February 2019

Educating Consumers on the Risks of Short-Term Plans Act of 2019 This bill requires health insurers offering short-term, limited-duration insurance coverage to prominently disclose all medical conditions for which an individual may be denied coverage, limited in coverage, or subject to a premium increase. (Short-term, limited-duration insurance coverage is designed to fill a temporary gap in insurance coverage.) Insurers must further disclose that this type of coverage is temporary, provides limited benefits, and is subject to termination. Insurers may not enroll an individual in a short-term, limited-duration insurance plan during any time in which that individual is eligible for open enrollment in coverage through the health insurance exchange.

Home Health Payment Innovation Act of 2019

United States · United States Congress · 11 February 2019

Home Health Payment Innovation Act of 2019 This bill makes a series of changes relating to payment and coverage of home health services under Medicare and Medicare Advantage (MA). Specifically, the bill allows the home-confinement requirement (also known as the homebound requirement) for home health services to be waived under Medicare and MA. Currently, as a condition of eligibility for such services, a physician must certify that an individual has difficulty leaving home without assistance (e.g., a wheelchair, special transportation, or help from another person) due to an illness or injury. The bill also alters the payment methodology under the Medicare prospective payment system for home health services, including by eliminating the requirement that such methodology include certain behavioral assumptions regarding the implementation of specified changes to units of payment and case-mix adjustment factors.

Mental Health Services for Students Act of 2020

United States · United States Congress · 8 February 2019

Mental Health Services for Students Act of 2019 This bill provides specific statutory authority for the Project AWARE (Advancing Wellness and Resiliency in Education) State Educational Agency Grant Program that is administered by the Substance Abuse and Mental Health Services Administration. The program supports school-based mental health services, including screening, treatment, and outreach programs.

Responsibly Addressing the Marijuana Policy Gap Act of 2019

United States · United States Congress · 8 February 2019

Responsibly Addressing the Marijuana Policy Gap Act of 2019 This bill removes federal restrictions on, and creates new protections for, marijuana-related conduct and activities that are authorized by state or tribal law (i.e., state-authorized). Among other things, the bill does the following: eliminates regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act for state-authorized marijuana-related activities; allows businesses that sell marijuana in compliance with state or tribal law to claim certain federal tax credits and deductions; eliminates restrictions on print and broadcast advertising of state-authorized marijuana-related activities; creates protections for depository institutions that provide financial services to marijuana-related businesses; specifies that a marijuana-related business is entitled to federal bankruptcy protections; establishes a process to expunge criminal records related to certain marijuana-related convictions; reestablishes federal student aid eligibility for certain students convicted of a misdemeanor offense for marijuana possession; exempts real property from civil forfeiture due to state-authorized marijuana-related conduct; prohibits the inadmissibility or deportability of aliens for state-authorized marijuana-related conduct; specifies that drug-related criminal activity, which is prohibited in federally assisted housing, does not include state-authorized marijuana-related conduct; establishes a new, separate registration process to facilitate medical marijuana research; authorizes health care providers employed by the Department of Veterans Affairs to recommend participation in state marijuana programs; and authorizes medical providers through an Indian health program to make medical recommendations regarding marijuana.

Accountability for Quality VA Healthcare Act

United States · United States Congress · 8 February 2019

Accountability for Quality VA Healthcare Act This bill requires the Department of Veterans Affairs (VA) to address functionality and accountability in regard to its facilities and provision of care. Specifically, the bill requires the VA to carry out a two-year pilot program to enhance the physical security of five selected VA medical facilities. The VA must submit a report that includes its plan and time frame to address specified findings and recommendations of the Government Accountability Office report titled VA Real Property: VA Should Improve Its Efforts to Align Facilities with Veterans' Needs . The bill requires the VA to update its Planning and Activating Community Based Outpatient Clinics handbook at least once every five years to reflect current policies and clarify the responsibilities of VA leasing project personnel. The VA must strengthen its medical facility inspection process and monitor women veterans' access to gender-specific care services under community care contracts, including appointment scheduling and completion times. Finally, the bill requires the VA to (1) clarify measures for medical appointment wait times in a manner that reduces the likelihood of misinterpretation, (2) ensure that patient indicated date (the earliest date the patient needs to be seen) is clearly defined for purposes of Veterans Health Administration scheduling and related training documents, (3) improve recruitment and retention of scheduling staff and require facilities to routinely assess scheduling and resource needs, and (4) improve telephone access at its medical facilities.

Expressing support for health and wellness coaches.

United States · United States Congress · 8 February 2019

This resolution expresses support for the efforts of health and wellness coaches.

Supporting the designation of March 2019 as Endometriosis Awareness Month.

United States · United States Congress · 8 February 2019

This resolution expresses support for the goals and ideas of Endometriosis Awareness Month. (Endometriosis is a painful condition in which the tissue that normally lines the inside of the uterus grows outside the uterus.) It also recognizes the need for early detection and treatment of endometriosis, increased education for health care providers, and more culturally competent care.

Expressing support for the designation of the 17th day in May as "DIPG Awareness Day" to raise awareness and encourage research into cures for diffuse intrinsic pontine glioma (DIPG) and pediatric cancers in general.

United States · United States Congress · 8 February 2019

This resolution expresses support for the designation of DIPG Awareness Day. (DIPG is diffuse intrinsic pontine glioma, a terminal childhood brain cancer.) It also encourages public and private sources of research funding to elevate their consideration of the mortality rate of a type of cancer as well as the life years lost as factors considered during the grant application process.

Collaborative Academic Research Efforts for Tourette Syndrome Act of 2019

United States · United States Congress · 8 February 2019

Collaborative Academic Research Efforts for Tourette Syndrome Act of 2019 This bill requires the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH research on Tourette syndrome. The NIH must (1) develop a system to collect data on Tourette syndrome, including epidemiological information and data on the availability of medical and social services for individuals with Tourette syndrome and their families; (2) support Collaborative Research Centers for Tourette Syndrome to conduct basic and clinical research; (3) award grants for research on Tourette syndrome symptoms and treatment options for particular patient subpopulations; and (4) designate funding to carry out Tourette syndrome programs and activities.

To require the Surgeon General of the Public Health Service to submit to Congress an annual report on the effects of gun violence on public health.

United States · United States Congress · 8 February 2019

This bill requires the Surgeon General to report annually to Congress on the public health effects of gun violence, as well as on the status of actions taken to address such effects.

Genetically Engineered Salmon Labeling Act

United States · United States Congress · 7 February 2019

Genetically Engineered Salmon Labeling Act This bill requires the market name of genetically engineered (commonly called genetically modified or GMO ) salmon to include Genetically Engineered or GE in front of the existing market name. The Department of Health and Human Services must ensure that an independent scientific organization conducts a review of the environmental assessment carried out by the Food and Drug Administration in support of a new drug related to AquAdvantage Salmon.

Autism CARES Act of 2019

United States · United States Congress · 7 February 2019

Autism Collaboration, Accountability, Research, Education, and Support Act of 2019 or the Autism CARES Act of 2019 This bill reauthorizes through FY2024 and revises several programs and activities relating to autism spectrum disorder (ASD). Among other things, the bill reauthorizes provisions relating to (1) expanded ASD research at the National Institutes of Health; (2) ASD education, early detection, and intervention activities supported by the Health Resources and Services Administration; and (3) the Interagency Autism Coordinating Committee. The bill also generally revises the scope of such programs and activities to encompass ASD individuals of all ages, rather than only youth.

Medicare Negotiation and Competitive Licensing Act of 2019

United States · United States Congress · 7 February 2019

Medicare Negotiation and Competitive Licensing Act of 2019 This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.) The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities. Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

Recognizing the duty of the Federal Government to create a Green New Deal.

United States · United States Congress · 7 February 2019

This resolution calls for the creation of a Green New Deal with the goals of achieving net-zero greenhouse gas emissions; establishing millions of high-wage jobs and ensuring economic security for all; investing in infrastructure and industry; securing clean air and water, climate and community resiliency, healthy food, access to nature, and a sustainable environment for all; and promoting justice and equality. The resolution calls for accomplishment of these goals through a 10-year national mobilization effort. The resolution also enumerates the goals and projects of the mobilization effort, including building smart power grids (i.e., power grids that enable customers to reduce their power use during peak demand periods); upgrading all existing buildings and constructing new buildings to achieve maximum energy and water efficiency; removing pollution and greenhouse gas emissions from the transportation and agricultural sectors; cleaning up existing hazardous waste and abandoned sites; ensuring businesspersons are free from unfair competition; and providing higher education, high-quality health care, and affordable, safe, and adequate housing to all.

Supporting the goals and ideals of National Black HIV/AIDS Awareness Day.

United States · United States Congress · 7 February 2019

This resolution expresses support for the goals and ideals of National Black HIV/AIDS Awareness Day.

SASCA

United States · United States Congress · 7 February 2019

To amend title XVIII of the Social Security Act to provide for direct payment to physician assistants under the Medicare program for certain services furnished by such physician assistants.

United States · United States Congress · 7 February 2019

This bill allows direct payment, under the Medicare program, to physician assistants for certain services furnished to enrollees.

Critical Access Hospital Relief Act of 2019

United States · United States Congress · 7 February 2019

Critical Access Hospital Relief Act of 2019 This bill repeals the 96-hour physician-certification requirement for inpatient critical access hospital services under Medicare. Under current law, as a condition for Medicare payment for such services, a physician must certify that a patient may reasonably be expected to be discharged or transferred to a hospital within 96 hours after admission to the critical access hospital.

Prescription Drug Price Transparency Act

United States · United States Congress · 7 February 2019

Prescription Drug Price Transparency Act This bill establishes additional requirements for prescription drug plan sponsors (PDPs) under Medicare and Medicare Advantage, as well as health insurance carriers under the Federal Employees Health Benefits Program, relating to the methodology of payments to pharmacies and the use of pharmacy benefits managers (PBMs). Specifically, such PDPs and carriers must disclose specified information to pharmacies regarding applicable standards for reimbursement that are based on drug costs, including the sources used to update such standards. Additionally, such PDPs and carriers may not contract with PBMs that require, or that provide an incentive for, plan enrollees to use pharmacies that have a shared ownership interest with the PBM.

Phair Pricing Act of 2019

United States · United States Congress · 7 February 2019

Phair Pricing Act of 2019 This bill requires that certain negotiated prices for covered drugs under the Medicare prescription drug benefit be disclosed at the point-of-sale. Specifically, negotiated prices offered under a prescription drug plan (PDP) must be disclosed at the point-of-sale; the disclosed price must include specified adjustments, payments, and fees that are negotiated with the pharmacy (e.g., dispensing fees) by the PDP sponsor or pharmacy benefit manager. Additionally, the Centers for Medicare & Medicaid Services must establish certain quality measures for PDP sponsors to use when determining incentive payments and adjustments (e.g., performance payments) to pharmacies.

Autism CARES Act of 2019

United States · United States Congress · 7 February 2019

Autism Collaboration, Accountability, Research, Education, and Support Act of 2019 or the Autism CARES Act of 2019 This bill reauthorizes through FY2024 and revises several programs and activities relating to autism spectrum disorder (ASD). Among other things, the bill reauthorizes provisions relating to (1) expanded ASD research at the National Institutes of Health; (2) ASD education, early detection, and intervention activities supported by the Health Resources and Services Administration; and (3) the Interagency Autism Coordinating Committee. The bill also generally revises the scope of such programs and activities to encompass ASD individuals of all ages, rather than only youth.

Budgeting for Opioid Addiction Treatment Act

United States · United States Congress · 7 February 2019

Budgeting for Opioid Addiction Treatment Act This bill imposes a one cent per milligram fee on the sale of active opioids by the manufacturer, producer, or importer. The fee excludes prescription drugs used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort. The Department of Health and Human Services (HHS) must establish a program to provide rebates or discounts to cancer and hospice patients to ensure that they do not pay the fee. Any increase in federal revenues from the fee after rebates and discounts are subtracted must be distributed to states under the Substance Abuse Prevention and Treatment Block Grant program. The states must use the funds exclusively for substance abuse (including opioid abuse) efforts in the states, including (1) specified treatment programs, and (2) the recruitment and training of substance use disorder professionals to work in rural and medically underserved communities. HHS must report to Congress on the impact of this bill on the retail cost of opioids and patient access to opioid medication, the effectiveness of the discount or rebate for cancer and hospice patients, how the funds are being used to improve substance abuse treatment efforts, and suggestions for improving access to opioids for cancer and hospice patients and substance abuse treatment efforts.

DEA Enforcement and Authority Act of 2019

United States · United States Congress · 7 February 2019

DEA Enforcement and Authority Act of 2019 This bill modifies enforcement authorities of the Drug Enforcement Administration (DEA). It modifies the required elements of an order to show cause issued by the DEA before it denies, revokes, or suspends a registration for a CSA violation. Specifically, the bill eliminates the requirement for an order to show cause to notify the registrant of the opportunity to submit a corrective action plan. Additionally, the bill modifies the standard of review for an immediate suspension order. Currently, the DEA may immediately suspend the registration of a controlled substances manufacturer, distributor, or dispenser to prevent imminent danger to the public health and safety. This bill lowers the standard for determining imminent danger to the public health and safety—from substantial likelihood of an immediate threat of harm to probable cause that harm will occur.

Responsibly Addressing the Marijuana Policy Gap Act of 2019

United States · United States Congress · 7 February 2019

Responsibly Addressing the Marijuana Policy Gap Act of 2019 This bill removes federal restrictions on, and creates new protections for, marijuana-related conduct and activities that are authorized by state or tribal law (i.e., state-authorized). Among other things, the bill does the following: eliminates regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act for state-authorized marijuana-related activities; allows businesses that sell marijuana in compliance with state or tribal law to claim certain federal tax credits and deductions; eliminates restrictions on print and broadcast advertising of state-authorized marijuana-related activities; creates protections for depository institutions that provide financial services to marijuana-related businesses; specifies that a marijuana-related business is entitled to federal bankruptcy protections; establishes a process to expunge criminal records related to certain marijuana-related convictions; reestablishes federal student aid eligibility for certain students convicted of a misdemeanor offense for marijuana possession; exempts real property from civil forfeiture due to state-authorized marijuana-related conduct; prohibits the inadmissibility or deportability of aliens for state-authorized marijuana-related conduct; specifies that drug-related criminal activity, which is prohibited in federally assisted housing, does not include state-authorized marijuana-related conduct; establishes a new, separate registration process to facilitate medical marijuana research; authorizes health care providers employed by the Department of Veterans Affairs to recommend participation in state marijuana programs; and authorizes medical providers through an Indian health program to make medical recommendations regarding marijuana.

Protecting Americans from Dangerous Opioids Act

United States · United States Congress · 7 February 2019

Protecting Americans from Dangerous Opioids Act This bill requires the Food and Drug Administration (FDA) to revoke approval for an opioid drug for every new opioid drug approved. (Opioids are drugs with effects similar to opium, such as certain pain medications.) In determining the drug for which to revoke approval, the FDA must prioritize revoking approval for drugs that are not abuse deterrent and consider the public health impact of drugs on the market.

FDA Accountability for Public Safety Act

United States · United States Congress · 7 February 2019

FDA Accountability for Public Safety Act This bill establishes additional procedures related to the market approval process for opioids. Under the bill, a Food and Drug Administration (FDA) advisory committee must make recommendations regarding supplemental applications for opioids. Current law requires only that an FDA committee make recommendations on new drug applications. The bill specifies that only the Commissioner of Food and Drugs may approve an opioid-related application against the recommendation of the committee. If the Commissioner approves such an application against a committee recommendation, the Commissioner must submit a report to Congress that includes (1) the evidence regarding patient safety that supports the Commissioner's decision, and (2) a disclosure of any potential conflicts of interest of FDA officials involved in the decision. The Commissioner must also testify before Congress regarding the decision, upon request. The drug in question may not be sold until the Commissioner has submitted the required report.

Changing the Culture of the FDA Act

United States · United States Congress · 7 February 2019

Changing the Culture of the FDA Act This bill requires the Food and Drug Administration to amend its mission statement to take responsibility for protecting the public health by considering the danger of addiction and overdose death when approving and regulating prescription opioid medications. (Opioid medications are drugs with effects similar to opium, such as certain pain medications.)

SASCA

United States · United States Congress · 7 February 2019

Survivors' Access to Supportive Care Act or SASCA This bill establishes a series of programs and requirements to address the adequacy of access to sexual-assault examinations. Among other things, the bill establishes (1) a grant program for states to assess the availability of specified providers to perform sexual-assault examinations; (2) a multiagency pilot program to improve training for, and access to, such providers; (3) reporting requirements for hospitals regarding community access to such providers; and (4) a grant program for provider training in rural and tribal settings.

Medicare Negotiation and Competitive Licensing Act of 2019

United States · United States Congress · 7 February 2019

Medicare Negotiation and Competitive Licensing Act of 2019 This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.) The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities. Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

A resolution recognizing the duty of the Federal Government to create a Green New Deal.

United States · United States Congress · 7 February 2019

This resolution calls for the creation of a Green New Deal with the goals of achieving net-zero greenhouse gas emissions; establishing millions of high-wage jobs and ensuring economic security for all; investing in infrastructure and industry; securing clean air and water, climate and community resiliency, healthy food, access to nature, and a sustainable environment for all; and promoting justice and equality. The resolution calls for accomplishment of these goals through a 10-year national mobilization effort. The resolution also enumerates the goals and projects of the mobilization effort, including building smart power grids (i.e., power grids that enable customers to reduce their power use during peak demand periods); upgrading all existing buildings and constructing new buildings to achieve maximum energy and water efficiency; removing pollution and greenhouse gas emissions from the transportation and agricultural sectors; cleaning up existing hazardous waste and abandoned sites; ensuring businesspersons are free from unfair competition; and providing higher education, high-quality health care, and affordable, safe, and adequate housing to all.

Strengthening Health Care and Lowering Prescription Drug Costs Act

United States · United States Congress · 6 February 2019

Marketing and Outreach Restoration to Empower Health Education Act of 2019 or the MORE Health Education Act This bill requires the Department of Health and Human Services (HHS) to conduct outreach and educational activities regarding federally-facilitated exchanges (i.e., health insurance exchanges that are established and operated within states by HHS). The activities must inform potential enrollees of the availability of coverage and related financial assistance under the exchanges and must be provided in culturally and linguistically appropriate formats.

Protecting Americans with Preexisting Conditions Act of 2019

United States · United States Congress · 6 February 2019

Protecting Americans with Preexisting Conditions Act of 2019 This bill nullifies the Department of the Treasury and the Department of Health and Human Services guidance titled "State Relief and Empowerment Waivers," published on October 24, 2018. The guidance pertains to Section 1332 waivers (also known as State Innovation Waivers or State Relief and Empowerment Waivers), which allow states to forego certain requirements of the Patient Protection and Affordable Care Act in order to implement experimental plans for health care coverage, as long as the resulting coverage meets certain statutory criteria. The guidance, which supersedes earlier guidance from 2015, alters agency interpretation of how states may satisfy the statutory criteria for waiver approval. For example, the guidance (1) redefines acceptable coverage under such waivers to include short-term, limited-duration insurance and association health plans; (2) allows the comprehensiveness and affordability of coverage under such waivers to be assessed based on projected availability, rather than enrollment; and (3) allows the level of coverage to be assessed based on the effects over the entire course of the waiver, rather than per year.

To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect.

United States · United States Congress · 6 February 2019

This bill nullifies a rule by the Department of Treasury, the Department of Labor, and the Department of Health and Human Services regarding short-term, limited-duration health insurance plans. Short-term, limited-duration health insurance plans are plans that may only offer coverage for a limited amount of time under law and that are exempt from the market requirements of the Patient Protection and Affordable Care Act (e.g., coverage of individuals with preexisting conditions). The rule increases the maximum authorized duration of such plans from less than 3 months (including renewals) to an initial maximum duration of less than 12 months (with a total duration of up to 36 months, including renewals). The rule took effect October 2, 2018.

Providing for the consideration of the bill (H.R. 962) to amend title 18, United States Code, to prohibit a health care practitioner from failing to exercise the proper degree of care in the case of a child who survives an abortion or attempted abortion.

United States · United States Congress · 6 February 2019

This resolution sets forth the rule for consideration of H.R. 962 (Born-Alive Abortion Survivors Protection Act). Rule XIX (Motions Following the Amendment Stage) of the Rules of the House of Representatives shall not apply to consideration of H.R. 962, with respect to certain motions for previous questions.

Protecting Sensitive Locations Act

United States · United States Congress · 6 February 2019

Protecting Sensitive Locations Act This bill prohibits immigration enforcement actions within 1,000 feet of a sensitive location unless there are exigent circumstances or if written prior approval has been obtained from certain officials. Sensitive locations include health care facilities; schools and school bus stops; places that provide assistance for people such as children, pregnant women, and abuse victims; places that provide disaster or emergency services; places of worship; courthouses and lawyers' offices; and public assistance offices. The prohibition shall apply to Department of Homeland Security officers and agents, as well as state employees pursuing immigration enforcement actions. If an enforcement action is carried out in violation of this prohibition (1) no information resulting from the action may be entered into the record in a resulting removal proceeding, and (2) the affected alien may move to immediately terminate such a proceeding. U.S. Immigration and Customs Enforcement and U.S. Customs and Border Protection shall annually report to Congress about enforcement actions taken at sensitive locations in the preceding year.

Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the final rule of the Department of the Treasury, the Department of Labor, and the Department of Health and Human Services relating to "Short-Term, Limited-Duration Insurance".

United States · United States Congress · 6 February 2019

Dental Loan Repayment Assistance Act

United States · United States Congress · 6 February 2019

Dental Loan Repayment Assistance Act This bill modifies the requirements for calculating taxable income to exclude from gross income payments received under the federally funded student loan repayment program for full-time faculty members of dental schools with programs in general, pediatric, or public health dentistry. The bill also requires the Government Accountability Office to report to Congress on the participation of dental providers and faculty in areas and schools receiving funding under the program.

Hatch-Waxman Integrity Act of 2019

United States · United States Congress · 6 February 2019

Hatch-Waxman Integrity Act of 2019 This bill establishes certain limits on the filing of patent validity challenges with the Patent Trial and Appeal Board, particularly with respect to inter partes review.

FLAT Prices Act

United States · United States Congress · 6 February 2019

Forcing Limits on Abusive and Tumultuous Prices or the FLAT Prices Act This bill directs the Food and Drug Administration to reduce the market exclusivity of an approved prescription drug if the drug manufacturer increases the drug's price by more than a specified percentage. This reduction may be waived under specified circumstances.

Dental Loan Repayment Assistance Act

United States · United States Congress · 6 February 2019

Dental Loan Repayment Assistance Act This bill modifies the requirements for calculating taxable income to exclude from gross income payments received under the federally funded student loan repayment program for full-time faculty members of dental schools with programs in general, pediatric, or public health dentistry. The bill also requires the Government Accountability Office to report to Congress on the participation of dental providers and faculty in areas and schools receiving funding under the program.

Competitive Health Insurance Reform Act of 2019

United States · United States Congress · 6 February 2019

Competitive Health Insurance Reform Act of 2019 This bill declares that nothing in the McCarran-Ferguson Act modifies, impairs, or supersedes the operation of antitrust laws with respect to the business of health insurance, including the business of dental insurance. This declaration does not apply to a contract, combination, or conspiracy to (1) collect, compile, or disseminate historical loss data; (2) determine a loss development factor for historical loss data; (3) perform actuarial services if the collaboration does not involve a restraint of trade; or (4) develop or disseminate a standard insurance policy form if adherence to the form is not required. Prohibitions against unfair methods of competition apply to the business of health insurance without regard to whether the business is for profit.

Resident Physician Shortage Reduction Act of 2019

United States · United States Congress · 6 February 2019

Resident Physician Shortage Reduction Act of 2019 This bill increases the number of residency positions eligible for graduate medical education payments under Medicare for qualifying hospitals, with an aggregate increase of 3,000 positions per fiscal year for five years. Of these positions, at least 1,500 per fiscal year must be for residents in a shortage specialty residency program (i.e., a program in a specialty in which baseline physician requirements projections exceed the projected supply of total active physicians, as identified by the Health Resources and Services Administration in a specified report).

Hatch-Waxman Integrity Act of 2019

United States · United States Congress · 6 February 2019

Hatch-Waxman Integrity Act of 2019 This bill establishes certain limits on the filing of patent validity challenges with the Patent Trial and Appeal Board, particularly with respect to inter partes review.

HOW PRIMARY CARE AFFECTS HEALTH CARE COSTS AND OUTCOMES

United States · United States Senate · 5 February 2019